1. Home
  2. Clinical Topics
  3. FDA approves biosimilar for adults with non-Hodgkin’s lymphoma
Clinical TopicsDrugs and DevicesWeb Exclusives
biosimilar adults non-hodgkins lymphoma

FDA approves biosimilar for adults with non-Hodgkin’s lymphoma

Share

On Nov. 28, the FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

Read more via U.S. Food & Drug Administration.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts